ArticlePloS one2017
Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Revolutionizing the Pancreatic Tumor Diagnosis: Emerging Trends in Imaging Technologies: A Systematic Review.Medicina (Kaunas, Lithuania) · 2024Pooled it
- European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations.United European gastroenterology journal · 2020Guideline
- Markedly Elevated CA 19-9 in ANA/ASMA-Negative IgG4-Related Autoimmune Hepatitis With Concomitant Pancreatitis: A Case Report.Case reports in gastrointestinal medicine · 2026Article
- CA19-9/DBil: a promising indicator to distinguish between CA19-9-elevated pancreatic head-type autoimmune pancreatitis and pancreatic head cancer.BMC gastroenterology · 2025Article
- Autoimmune pancreatitis: Cornerstones and future perspectives.World journal of gastroenterology · 2024Review
- Diagnostic Differentiation between Pancreatitis and Pancreatic Cancer: A Scoping Review.Diagnostics (Basel, Switzerland) · 2024Article
- Multiparameter diagnostic model based onQuantitative imaging in medicine and surgery · 2023Article
- Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma.World journal of gastrointestinal oncology · 2023Review
- Challenges for clinicians treating autoimmune pancreatitis: Current perspectives.World journal of clinical cases · 2023Review
- Characteristics of mass-forming autoimmune pancreatitis commonly misdiagnosed as a malignant tumor.Frontiers in surgery · 2023Article
- Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.Current oncology (Toronto, Ont.) · 2022Review
- The Clinical Utility of Soluble Serum Biomarkers in Autoimmune Pancreatitis: A Systematic Review.Biomedicines · 2022Review
- Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review.Cancer communications (London, England) · 2021Review
- Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.World journal of gastrointestinal surgery · 2020Review
- Autoimmune pancreatitis masquerading as pancreatic cancer: case report of a Chinese man.International journal of clinical and experimental pathology · 2019Article
- Autoimmune pancreatitis with concomitant autoimmune haemolytic anaemia.BMJ case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune pancreatitis (AIP) is a special type of chronic pancreatitis, which may be misdiagnosed as pancreatic carcinoma. This study aims to verify new biomarkers for AIP and propose a serological pattern to differentiate AIP from pancreatic adenocarcinoma with routinely performed tests. In this study, data of serum samples were collected and compared between 25 patients with AIP and 100 patients with pancreatic carcinoma. Receiver operating characteristic analysis and logistic regression was performed to evaluate the diagnostic effect of serum parameters in differentiating AIP from pancreatic carcinoma alone or in combination. Among several serum markers observed in the two groups, carbohydrate antigen 19-9 (Ca19-9), globulin, eosinophils and hemoglobin were selected as the independent markers. Serum levels of Globulin, Eosinophil percentage in AIP group were significantly higher than in pancreatic cancer group (P<0.05), while hemoglobin and tumor marker CA19-9 levels were lower (P <0.05). The combination of these markers identified patients with AIP with 92% sensitivity and 79% specificity, which indicated relatively high diagnostic value. Elevated serum eosinophils, globulin, together with decreased hemoglobin level can be used as a preoperative indicator for AIP and can help to initiate diagnosis of AIP in time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.